Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Laser zap before eye injection could cut needle count for wet AMD

NCT ID NCT07744204

Disease control Sponsor: Chinese PLA General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 04, 2026 · Last updated Aug 20, 2026 · Updated 3 times

Summary

This study tests whether a low-intensity laser applied to the diseased area just before an anti-VEGF injection helps the drug work better in people with wet age-related macular degeneration (AMD). Wet AMD causes abnormal blood vessels to leak fluid under the retina, and current treatment requires frequent eye injections. The trial will compare patients who receive laser plus injection versus injection alone, tracking how many injections are needed over 24 months. If the laser enhances drug delivery, patients may need fewer injections, reducing the burden of treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Laser photocoagulation (577-nm yellow laser) combined with anti-VEGF injections (conbercept, aflibercept, ranibizumab, or faricimab)
What this could lead to
If successful, this approach could reduce the number of eye injections needed for wet AMD, easing the treatment burden for patients.
What could go wrong
The trial is relatively small and early, and the laser may not enhance drug delivery as hoped. There are also risks of laser-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 240 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Jul 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 50 years, male or female * Diagnosed with neovascular age-related macular degeneration (nAMD) based on multimodal imaging (fundus photography, OCT, FFA, ICGA), including type 1, type 2, or type 3 MNV, or PCV * Clear ocular media and adequate pupillary dilation to permit OCT, fundus photography, angiography, and laser photocoagulation * Active MNV in the study eye at least partially located ≥ 300 μm from the foveal centre * Willing and able to provide written informed consent * Only one eye per subject enrolled; if both eyes eligible, the study eye is selected by the investigator Exclusion Criteria: * Active MNV entirely located within 300 μm of the foveal centre * Significant hemorrhage obscuring the active MNV lesion on FFA/ICGA Unwilling or unable to provide informed consent, refusal of randomization, or inability to complete scheduled follow-up visits * Concurrent participation in other clinical trials * Contraindication or allergy to FFA/ICGA * Coexisting ocular conditions that may affect visual acuity during follow-up (e.g., cataract, diabetic retinopathy, retinal vascular occlusion, uveitis, neovascular glaucoma) * Severe ocular surface infection (e.g., conjunctivitis, severe blepharitis) * Uncontrolled hypertension (blood pressure \> 180/110 mmHg) despite antihypertensive therapy * Any condition in the study eye or systemically that, in the investigator's opinion, would pose significant risk to the participant * Poorly controlled blood glucose in diabetic patients * Transient ischemic attack, stroke, myocardial infarction, acute congestive heart failure, or other acute cardiovascular event requiring hospitalization within the past 4 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neovascular age-related macular degeneration (NAMD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neovascular age-related macular degeneration (NAMD) Wet macular degeneration

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.